VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 107 filers reported holding VAXCYTE INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $43,078,100 | +2.1% | 845,000 | 0.0% | 3.18% | -2.4% |
| Q2 2023 | $42,199,300 | +51.1% | 845,000 | +13.4% | 3.26% | +77.0% |
| Q1 2023 | $27,922,600 | -19.7% | 745,000 | +2.8% | 1.84% | -15.1% |
| Q4 2022 | $34,763,750 | +75.8% | 725,000 | -12.0% | 2.17% | +130.1% |
| Q3 2022 | $19,769,000 | +10.3% | 823,705 | 0.0% | 0.94% | +6.8% |
| Q2 2022 | $17,924,000 | +117.7% | 823,705 | +97.6% | 0.88% | +159.7% |
| Q1 2021 | $8,235,000 | -25.7% | 416,937 | 0.0% | 0.34% | -28.4% |
| Q4 2020 | $11,078,000 | -65.6% | 416,937 | -36.0% | 0.48% | -70.2% |
| Q3 2020 | $32,159,000 | +15.4% | 651,255 | -26.2% | 1.60% | -11.3% |
| Q2 2020 | $27,877,000 | – | 881,898 | – | 1.80% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |